1-20 of 20
Can Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial

Othman Al-Sawaf, Benjamin N. Locher, Friederike Christen, Sandra Robrecht, Can Zhang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl Anton Kreuzer, Coral Fustero, Raphael Hablesreiter, John F. Seymour, Piers Blombery, Lars Bullinger, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael J. Hallek, Kirsten Fischer, Frederik Damm
Journal: Blood
Blood (2024) 144 (Supplement 1): 4613.
https://doi.org/10.1182/blood-2024-208727
Published: 2024
Journal Articles

Telomere Length Associations with Characteristics and Outcome in Patients Treated with Venetoclax-Based First-Line Combinations in the GAIA/CLL13 Study

Billy Jebaraj, Eugen Tausch, Deyan Y. Yosifov, Christof Schneider, Moritz Fürstenau, Can Zhang, Sandra Robrecht, Caspar da Cunha-Bang, Mark-David Levin, Philipp Bernhard Staber, Tamar Tadmor, Patrick Thornton, Michael Gregor, Anna Maria Fink, Kirsten Fischer, Matthias Ritgen, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2024) 144 (Supplement 1): 4626.
https://doi.org/10.1182/blood-2024-204852
Published: 2024
Journal Articles

Impact of Ibrutinib on Quality of Life in Patients with Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia: Results from the Phase III CLL12 Trial

Ellinor Goergen, Sandra Robrecht, Adam Giza, Can Zhang, Pascal Nieper, Florian Simon, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Nadine Kutsch, Anna Maria Fink, Ursula Vehling-Kaiser, Lothar Müller, Michael J. Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Beate Stauch, Clemens-Martin Wendtner, Eugen Tausch, Christof Schneider, Kirsten Fischer, Stephan Stilgenbauer, Barbara F. Eichhorst, Michael Hallek, Petra Langerbeins
Journal: Blood
Blood (2024) 144 (Supplement 1): 1859.
https://doi.org/10.1182/blood-2024-200903
Published: 2024
Journal Articles

Venetoclax May Overcome the Prognostic Disadvantage of Short Telomeres Regarding Progression Free Survival in Previously Untreated CLL Patients with Coexisting Conditions: A Study By the German CLL Study Group (GCLLSG)

Lukas Peter Frenzel, Laura Beckmann, Sandra Robrecht, Can Zhang, Anna Maria Fink, Othman Al-Sawaf, Christof Schneider, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Tim H. H. Brummendorf, Michael Hallek, Barbara F. Eichhorst, Kirsten Fischer, Fabian Beier, Susanne Isfort
Journal: Blood
Blood (2024) 144 (Supplement 1): 3250.
https://doi.org/10.1182/blood-2024-200075
Published: 2024
Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Clinical Trials & Observations
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivchev, Carsten Utoft Niemann, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S. Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva D. Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Journal: Blood
Blood (2024) 144 (18): 1924–1935.
https://doi.org/10.1182/blood.2024024631
Published: 2024
Includes: Supplemental data
Journal Articles

First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial

Moritz Fürstenau, Matthias Ritgen, Sandra Robrecht, Julia Von Tresckow, Can Zhang, Anke Schilhabel, Michael Gregor, Patrick Thornton, Philipp Bernhard Staber, Tamar Tadmor, Vesa Lindström, Gunnar Juliusson, Ann Janssens, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Neta Goldschmidt, Elisabeth Vandenberghe, Davide Rossi, Rudolf A. Benz, Daniel Heintel, Christian Bjørn Poulsen, Ilse Christiansen, Henrik Frederiksen, Lisbeth Enggaard, Eduardus Posthuma, Djamila Issa, Hein Visser, Mar Bellido, Nadine Kutsch, Jan Dürig, Alexander Stehle, Matthias C. Voehringer, Sebastian Böttcher, Clemens Schulte, Florian Simon, Anna-Maria Fink, Kirsten Fischer, Emily Holmes, Karl-Anton Kreuzer, Monika Brüggemann, Eugen Tausch, Stephan Stilgenbauer, Michael Hallek, Arnon P. Kater, Carsten Utoft Niemann, Barbara F. Eichhorst
Journal: Blood
Blood (2023) 142 (Supplement 1): 635.
https://doi.org/10.1182/blood-2023-173709
Published: 2023
Journal Articles

Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/ TP53 mut

Clinical Trials & Observations
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Othman Al-Sawaf, Karl-Anton Kreuzer, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2023) 142 (11): 961–972.
https://doi.org/10.1182/blood.2023020013
Published: 2023
Includes: Supplemental data
Journal Articles

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/ TP53 Mutation

Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia Von Tresckow, Sandra Robrecht, Adam Giza, Can Zhang, Moritz Furstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna Lena Illert, Jan Dürig, Sebastian Böttcher, Carsten Utoft Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 140 (Supplement 1): 834–836.
https://doi.org/10.1182/blood-2022-163245
Published: 2022
Journal Articles

Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia

Clinical Trials & Observations
Henriette Huber, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht, Can Zhang, Eugen Tausch, Christof Schneider, Johannes Bloehdorn, Moritz Fürstenau, Peter Dreger, Matthias Ritgen, Thomas Illmer, Anna L. Illert, Jan Dürig, Sebastian Böttcher, Carsten U. Niemann, Michael Kneba, Anna-Maria Fink, Kirsten Fischer, Hartmut Döhner, Michael Hallek, Barbara Eichhorst, Stephan Stilgenbauer
Journal: Blood
Blood (2022) 139 (9): 1318–1329.
https://doi.org/10.1182/blood.2021013208
Published: 2022
Includes: Supplemental data
Journal Articles

The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia

Clinical Trials & Observations
Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood
Blood (2022) 139 (2): 177–187.
https://doi.org/10.1182/blood.2021010845
Published: 2022
Includes: Supplemental data
Journal Articles

Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial

Moritz Fürstenau, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek, Barbara Eichhorst
Journal: Blood
Blood (2021) 138 (Supplement 1): 2639.
https://doi.org/10.1182/blood-2021-147790
Published: 2021
Journal Articles

ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia

Matthew S. Davids, Kirsten Fischer, Sandra Robrecht, Can Zhang, Inhye E. Ahn, Michele Porro Lurà, Wendy Sinai, Brenda Chyla, Kavita Sail, John Pesko, Madhavi Pai, Viktor Komlosi, Michael Hallek, Jennifer R. Brown, Othman Al-Sawaf
Journal: Blood
Blood (2021) 138 (Supplement 1): 2634.
https://doi.org/10.1182/blood-2021-153033
Published: 2021
Journal Articles

High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial

Moritz Fürstenau, Anke Schilhabel, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Eugen Tausch, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Marinus H.J. Van Oers, Caspar Da Cunha-Bang, Christian H. Geisler, Stephan Stilgenbauer, Monika Brüggemann, Michael Hallek, Matthias Ritgen, Barbara Eichhorst
Journal: Blood
Blood (2021) 138 (Supplement 1): 72.
https://doi.org/10.1182/blood-2021-147729
Published: 2021
Journal Articles

A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial

Barbara Eichhorst, Carsten Niemann, Arnon P. Kater, Moritz Fürstenau, Julia Von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindström, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Marjolein van der Klift, Ulrich Jaeger, Henrik Frederiksen, Maria B.L. Leijs, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry R. Koene, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Mark-David Levin, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek
Journal: Blood
Blood (2021) 138 (Supplement 1): 71.
https://doi.org/10.1182/blood-2021-146161
Published: 2021
Journal Articles

Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Cameron Wilson, Maneesh Tandon, MD, Travers Ching, Anna-Maria Fink, MD, Matthias Ritgen, MD, Eugen Tausch, MD, Karl-Anton Kreuzer, MD, William Schary, PhD, Clemens-Martin Wendtner, Barbara Eichhorst, MD, Stephan Stilgenbauer, MD, Yanwen Jiang, Michael Hallek, Kirsten Fischer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-136977
Published: 2020
Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Paula Cramer, Carmen D. Herling, MD PhD, Julia Von Tresckow, MD, Elisabeth Lange, MD, Sebastian Böttcher, MD PhD, Michael G. Kiehl, MD PhD, Martin Dreyling, MD, Ulrich Jaeger, Michael Gregor, MD, Ursula Vehling-Kaiser, MD, Matthias Ritgen, MD, Jan Dürig, MD, Eugen Tausch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Valentin Goede, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Petra Langerbeins, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139242
Published: 2020
Journal Articles

Bendamustine Followed By Obinutuzumab and Idelalisib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BCG Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, Julia Von Tresckow, MD, Anna-Maria Fink, MD, Gracia Braun, Sandra Robrecht, PhD, Can Zhang, PhD, Eugen Tausch, MD, Lothar Müller, MD, Wolfgang Knauf, MD, Othman Al-Sawaf, MD, Benedikt Pelzer, MD, Petra Langerbeins, MD, Kirsten Fischer, MD, Karl-Anton Kreuzer, MD, Matthias Ritgen, MD, Michael Kneba, MDPhD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Barbara Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
https://doi.org/10.1182/blood-2020-134827
Published: 2020
Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Clinical Trials & Observations
Eugen Tausch, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, Othman Al-Sawaf, Matthias Ritgen, Anna-Maria Fink, Barbara Eichhorst, Karl-Anton Kreuzer, Maneesh Tandon, Kathryn Humphrey, Yanwen Jiang, William Schary, Lars Bullinger, Daniel Mertens, Michele Porro Lurà, Michael Kneba, Hartmut Döhner, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer
Journal: Blood
Blood (2020) 135 (26): 2402–2412.
https://doi.org/10.1182/blood.2019004492
Published: 2020
Includes: Supplemental data
Journal Articles

Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group

Anna Maria Fink, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Nadine Kutsch, MD, Moritz Fürstenau, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Michael Kneba, MD PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Kirsten Fischer, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3040.
https://doi.org/10.1182/blood-2019-125063
Published: 2019
Journal Articles

Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (> 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)

Nisha De Silva, MBBS, MRCP, FRCPath, Sandra Robrecht, PhD, Can Zhang, PhD, Paula Cramer, Anna- Maria Fink, MD, Kirsten Fischer, MD, Valentin Goede, MD, Carmen D. Herling, MD PhD, Manuela Hoechstetter, MD, Clemens-Martin Wendtner, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4293.
https://doi.org/10.1182/blood-2019-126528
Published: 2019